Short-Term Safety of Low-Dose Creatine Hydrochloride: A 28-Day Single-Arm Pilot Study
Part of paid clinical trials in Raritan, New Jersey.
- Sponsor
- Vireo Systems, Inc.
- Study ID
- NCT07521059
- Status
- Completed
Conditions
- Safety of Short Term Creatine Hydrochloride Dosing
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 60 Years
- Healthy Volunteers
- Accepted
Interventions
- creatine supplementation — DIETARY_SUPPLEMENT750 mg/day dosing
Study Details
Background: Creatine monohydrate (typically 5-20 g/day) has a well-established safety profile across diverse populations. Creatine hydrochloride (CR-HCl) is a highly soluble creatine formulation that may allow effective supplementation at substantially lower doses (750 mg - 3 g/day); however, controlled human safety data specific to CR-HCl remain limited. Objective: To evaluate the short-term laboratory safety and tolerability of low-dose CR-HCl supplementation administered for 28 days in healthy adults.
Key Dates
- Start date
- May 30, 2024
- Status verified
- Apr 2026
- Primary completion
- Jul 3, 2024
- Completion
- Oct 1, 2024
Study Design
- Enrollment
- 11 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Group A 750mg/day
Primary Outcome Measure
No adverse events [ Time Frame: over 28 days ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Princeton Consumer Research | Raritan | New Jersey | 08869 | - |
Find similar trials in Raritan, NJ
By research site